Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Filings indexed 1,576 across all filing types
Latest filing 2023-05-31 Director's Dealing
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-05-31 English
FORM 4 SUBMISSION
Director's Dealing
2023-05-31 English
FORM 4 SUBMISSION
Director's Dealing
2023-05-31 English
Form 10-Q - Q1 2023
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q filed with the U.S. Securities and Exchange Commission by Oramed Pharmaceuticals Inc. for the quarterly period ended March 31, 2023. It contains interim condensed consolidated financial statements, management's discussion and analysis, and other required disclosures. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements is classified as an Interim / Quarterly Report (IR). Q1 2023
2023-05-12 English
Form 10-Q - Q1 2023
Report Publication Announcement Classification · 99% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' under Israeli regulations and, crucially, announces the attachment of a '*Form 10-Q - Q1 2023*'. A Form 10-Q is the standard SEC filing for quarterly financial reports. Since this document is an announcement stating that the actual comprehensive quarterly report (the 10-Q) is attached, it fits the definition of a Report Publication Announcement (RPA) based on the 'MENU VS MEAL' rule. It is not the full 10-Q itself, but the notice of its publication. The document length (1917 chars) is also very short, supporting the RPA classification.
2023-05-12 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2023
2023-05-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.